Remove 2025 Remove Radiation Remove Radiopharmaceuticals
article thumbnail

Dr. Sameer Keole voted President-elect of the American Society for Radiation Oncology (ASTRO)

Imaging Technology

milla1cf Thu, 07/20/2023 - 20:11 July 20, 2023 — The members of the American Society for Radiation Oncology ( ASTRO ) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole , MD, FASTRO , as President-elect; Wendy Woodward , MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S.

article thumbnail

Imaging societies' reactions mixed on finalized MPFS, HOPPS rules

AuntMinnie

Centers for Medicare & Medicaid Services (CMS) 2025 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules. Although the 2025 MPFS calls for an overall 2.9% The change to the MPFS conversion factor reflects the 0% update required by statute for 2025, the expiration of the 2.9%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 98
article thumbnail

Meet the Minnies 2024 semifinal candidates

AuntMinnie

Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. Quantifying Regional Radiation-Induced Lung Injury in Patients Using Hyperpolarized 129Xe Gas Exchange Magnetic Resonance Imaging. Rankine, et al, International Journal of Radiation Oncology, Biology, Physics , September 1, 2023.

article thumbnail

Blue Earth Therapeutics Reports Promising Phase 1 Data for Investigational Therapies

Imaging Technology

Radiation dosimetry performed for up to three cycles showed delivery of high tumor absorbed radiation doses relative to the dose delivered to the key normal organs, such as kidney and salivary glands. In combination with the positive radiation dosimetry results seen in Phase 1 for Lutetium ( 177 Lu) rhPSMA-10.1